Paratek Pharmaceuticals Inc (NASDAQ:PRTK) shares have surged over 30% in after-hours after the company reported positive results from a phase 3 study of Omadacycline in community-acquired bacterial pneumonia. Specifically, Omadacycline met all FDA primary and secondary endpoints and EMA co-primary...
[[ This is a content summary only. Visit my website for full links, other content, and more! ]]
April 04, 2017 at 03:57AM
http://ift.tt/2nCJqqC
from Insider Monkey Team
http://ift.tt/2nCJqqC
No comments:
Post a Comment